An alternative option
For patients who are discussing conventional fillers and want to explore an autologous, PRP-based approach as part of the conversation.
Ve
Regenerative Aesthetics
Velora The Non-Filler Filler™
An autologous, three-step system combining PRP and non-cross-linked hyaluronic acid with light photoactivation and controlled thermal incubation to form an injectable fibrin matrix.
Regenerative aesthetics
Autologous. Customizable.
Prepared at the point of care.
Velora pairs the patient's own platelet-rich plasma with non-cross-linked hyaluronic acid, then uses light photoactivation and controlled thermal incubation to form an injectable fibrin matrix.
- Autologous & Biocompatible
- Customizable Consistency
- Prepared at the point of care
The three-step system
From PRP to fibrin matrix
- 01
Combine
PRP + non-cross-linked HA
The patient's own platelet-rich plasma (PRP) is combined with non-cross-linked hyaluronic acid.
- 02
Photoactivate
Polychromatic light · 600–1200 nm
The mixture is exposed to polychromatic light in the 600–1200 nm range, which the manufacturer describes as a means of platelet activation.
- 03
Bio-incubate
Controlled thermal incubation
Controlled thermal bio-incubation forms an injectable fibrin matrix prepared at the point of care.
Autologous PRP
Built from the patient's own plasma
Velora begins with autologous platelet-rich plasma prepared from the patient's own blood sample, combined with non-cross-linked hyaluronic acid rather than a pre-manufactured cross-linked gel.
Customizable consistency
Tailored by the provider
Preparation allows the consistency of the resulting fibrin matrix to be adjusted, giving providers flexibility in how the protocol is applied.
Protocol possibilities
Three ways to integrate Velora into your practice
These are manufacturer-positioned professional protocol possibilities for discussion — not established efficacy or safety comparisons. Treatment planning remains the clinical judgment of the licensed provider.
A complement to precision HA filler
Positioned by the manufacturer as a protocol that may be considered alongside cross-linked HA filler within an individualized plan.
An addition to biostimulator planning
Positioned by the manufacturer as a protocol that may be discussed within broader biostimulator treatment planning.
Individualized planning
Complementary Aesthetic Technologies
Exosome-based skincare and professional skin treatments may be discussed as separately evaluated adjuncts within broader aesthetic plans. Each requires its own review of product-specific regulatory status, intended use and patient suitability by a qualified provider.
This is not a recommendation to mix or inject exosomes with Velora, and does not imply synergy or improved clinical outcomes.
In-office workflow
Equipment involved
Velora is a device-supported protocol. Practices should plan for the equipment below; confirm exact requirements with the manufacturer.
Centrifuge
Typically used to prepare PRP from the patient's blood sample.
Photoactivator
Delivers polychromatic light in the 600–1200 nm range.
Plasma incubator
Provides the controlled thermal bio-incubation step.
For providers
Why practices explore Velora
Versatility
Consistency can be customized during preparation, supporting discussion of different provider techniques and protocols.
Kit yield
An average of 10–13 cc per kit, as reported by the manufacturer. Actual yield may vary.
Autologous story
A patient-derived preparation that gives providers a distinct conversation within their aesthetic offering.
Practice integration
An in-office workflow that builds on existing PRP familiarity, staff routines and treatment-planning conversations.
FAQ
Common questions
What does “biological filler” mean here?
It describes Velora's approach: an injectable fibrin matrix prepared from the patient's own (autologous) PRP combined with non-cross-linked hyaluronic acid.
What is autologous PRP?
Platelet-rich plasma prepared from the patient's own blood sample at the point of care.
What is the role of the 600–1200 nm light?
Manufacturer materials describe polychromatic light photoactivation in this range as a step in platelet activation within the protocol.
Can the consistency be adjusted?
Yes. The protocol allows the consistency of the prepared matrix to be customized by the provider.
What is its regulatory status?
Regulatory status and indications should be reviewed product-specifically before any clinical or marketing use. Nothing on this page is a claim of safety, efficacy, duration or suitability for any indication.
How is pricing handled?
Pricing and partnership terms are discussed directly with qualified professionals. Schedule a consultation for details.
Discuss Velora for your practice
Book a consultation to review the protocol, manufacturer materials and partnership terms.
Regulatory note. Products in this portfolio do not share a single regulatory status, and some are not FDA-approved or cleared. Product-specific regulatory information must be reviewed before any marketing use. Nothing on this site is a claim of safety, efficacy, or suitability for any indication.